RESUMO
PET-driven SBRT plus pembrolizumab as first-line therapy against pleomorphic Pancoast cancer appears beneficial, probably due to high equivalent doses of SBRT on photopenic necrotic core and synergic immune system stimulation of immunoradiotherapy.
RESUMO
Malignancy-associated hypercalcemia is a complication of advanced tumours that is associated to a poor prognosis. Thorough evaluation to establish its cause is essential because some patients may actually have undiagnosed primary hyperparathyroidism. We report a case of a patient affected by Hodgkin's Lymphoma and persistent hypercalcemia with an incidental 18F-FDG PET/CT finding in the anterior neck region, not ascribable to malignancy, confirmed with 99mTc-sestamibi scintigraphy. It was removed by minimally invasive surgery. It was shown to be an oxyphil parathyroid adenoma localized in an unusual site (AU)
La hipercalcemia es una complicación de tumores avanzados y se asocia a un mal pronóstico. Llevar a cabo una evaluación para establecer la causa es esencial dado que algunos pacientes oncológicos pueden presentar hipercalcemia por hiperparatiroidismo primario no diagnosticado. Se describe el caso de un paciente con linfoma de Hodgkin y con hipercalcemia persistente en el cual un estudio 18F-FDG PET/TC mostró una lesión en la región anterior del cuello, no atribuible a la neoplasia inicial, confirmada por 99mTc-sestamibi y resecada con cirugía mínimamente invasiva. Era un adenoma oxifílico de paratiroides de localización ectópica (AU)